A Future Beyond the Burden of Disease
Elisigen develops gene therapies that target the root causes of disease. We are committed to delivering durable solutions for vision loss, chronic pain, and other conditions that have long conditions that have long burdened patients.
Advancing Gene Delivery to Improve Patient Care
To reduce the need for repeated dosing, we focus on AAV-based approaches engineered for durable, long-term therapeutic protein expression in vivo—improving both clinical outcomes and the patient experience.
Reduced Dosing Burden
Significantly reduces the burden of frequent re-dosing compared to conventional protein therapies.
In Vivo Production
Delivers therapeutic genes so that the patient’s own cells can directly produce the necessary proteins.
Durable Benefit
Sustained transgene expression supports long-lasting therapeutic efficacy supports long-lasting therapeutic efficacy.
Advancing gene delivery to reduce disease burden
To reduce the need for repeated dosing, we focus on AAV-based approaches engineered for durable, long-term therapeutic protein expression in vivo—improving both clinical outcomes and the patient experience.
